Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2023年11月20日 - 10:00PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-163
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of November 2023
Alterity
Therapeutics Limited
(Name
of Registrant)
Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980
and 333-228671) and our
Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417
and 333-250076)
ALTERITY
THERAPEUTICS LIMITED
(a
development stage enterprise)
The
following exhibits are submitted:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
|
|
|
By: |
/s/ Geoffrey P. Kempler |
|
|
Geoffrey P. Kempler |
|
|
Chairman |
Date:
November 20, 2023
2
Exhibit 99.1
Market
Announcement
20
November 2023
Alterity
Therapeutics Limited (ASX: ATH) – Trading Halt
Description
The
securities of Alterity Therapeutics Limited (‘ATH’) will be placed in trading halt at the request of ATH, pending it releasing
an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal
trading on Wednesday, 22 November 2023 or when the announcement is released to the market.
Issued
by
Melissa
Kostopoulos
Senior
Adviser, Listings Compliance
20 November 2023 |
Market Announcement 1/1 |
ASX Limited |
ASX Customer Service Centre 131 279 | asx.com.au |
20
November 2023
Melissa
Kostopoulos
Compliance
Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
Level
50, South Tower, Rialto
525 Collins St
Melbourne
VIC 3000
By email: |
tradinghaltsmelbourne@asx.com.au |
Dear
Melissa
Request
for a trading halt – Alterity Therapeutics Limited
In
accordance with ASX Listing Rule 17.1, Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (the Company) requests that its
securities be placed into an immediate trading halt pending an announcement in relation to a capital raise.
The
Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on
Wednesday, 22 November 2023, whichever is the earlier.
The
Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform
the market about the trading halt.
Please
contact me if you require any further information.
Yours sincerely
Phillip
Hains
Company Secretary
Alterity
Therapeutics Limited ABN 37 080 699 065
Level
14, 350 Collins Street, Melbourne, VIC 3000 Australia
T:
+61 (0)3 9349 4906 | www.alteritytherapeutics.com
Alterity Therapeutics (PK) (USOTC:PRNAF)
過去 株価チャート
から 8 2024 まで 9 2024
Alterity Therapeutics (PK) (USOTC:PRNAF)
過去 株価チャート
から 9 2023 まで 9 2024